Skip to main content
SpringerLink
Log in

Treatments for Comorbid Anxiety and Mood Disorders

  • Chapter
  • First Online:
Evidence-Based Herbal and Nutritional Treatments for Anxiety in Psychiatric Disorders

  • 1312 Accesses

Abstract

This chapter was included in the current book because of the high degree of comorbidity between anxiety and mood disorders that are commonly experienced by physicians when patients first present for treatment. In recent years, strong evidence has been presented for the efficacy of these substances in addressing mood disorders.

  • St John’s wort (Hypericum perforatum)

  • Saffron (Crocus sativus)

  • ω-3 polyunsaturated fatty acids

  • Zinc

  • SAMe (S-Adenosyl methionine)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kessler RC et al. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med. 2008;38(3):365–74.

    Article  CAS  PubMed  Google Scholar 

  2. Mellman TA. Sleep and anxiety disorders. Psychiatr Clin North Am. 2006;29(4):1047–58 ; abstract x.

    Article  PubMed  Google Scholar 

  3. Roth T. Insomnia as a risk factor for depression. Int J Neuropsychopharmacol. 2004;7:S34–5.

    Google Scholar 

  4. Brady KT, Verduin ML. Pharmacotherapy of comorbid mood, anxiety, and substance use disorders. Subst Use Misuse. 2005;40(13–14):2021–41 ,2043–8.

    Article  PubMed  Google Scholar 

  5. Nierenberg AA. Current perspectives on the diagnosis and treatment of major depressive disorder. Am J Manag Care. 2001;7(Suppl11):S353–66.

    CAS  PubMed  Google Scholar 

  6. Sarris J et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled, cross-over trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl). 2009;205(3):399–407.

    Article  CAS  Google Scholar 

  7. Sarris J et al. Nutritional medicine as mainstream in psychiatry. Lancet Psychiatry. 2015;2(3):271–4.

    Article  PubMed  Google Scholar 

  8. Sarris J, Kavanagh DJ. Kava and St John’s wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med. 2009;15(8):827–36.

    Article  PubMed  Google Scholar 

  9. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807–14.

    Article  Google Scholar 

  10. Shelton RC et al. Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978–86.

    Article  CAS  PubMed  Google Scholar 

  11. Fournier J et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Werneke U, Horn O, Taylor D. How effective is St John’s wort? The evidence revisited. J Clin Psychiatry. 2004;65(5):611–7.

    Article  PubMed  Google Scholar 

  13. Butterweck V, Schmidt M. St. John’s wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr. 2007;157(13–14):356–61.

    Article  PubMed  Google Scholar 

  14. Butterweck V. Mechanism of action of St John’s wort in depression : what is known? CNS Drugs. 2003;17(8):539–62.

    Article  CAS  PubMed  Google Scholar 

  15. Sublette, M., S. Ellis, A. Geant and J. Mann (2011). “Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression.” J Clin Psychiatry 72(12): 1577-1584.

    Google Scholar 

  16. Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a ‘modern’ herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449–68.

    Article  CAS  PubMed  Google Scholar 

  17. Schulz HU et al. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. Arzneimittelforschung. 2005;55(10):561–8.

    CAS  PubMed  Google Scholar 

  18. Biber A. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry. 1998;31(Suppl 1):36–43.

    Article  CAS  PubMed  Google Scholar 

  19. Linde K, Berner M, Kriston L. St John’s wort for major depression. Cochrane Database Syst Rev. 2008;4:CD000448.

    Google Scholar 

  20. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):118–27.

    Article  CAS  PubMed  Google Scholar 

  21. Taylor LH, Kobak KA. An open-label trial of St. John’s Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry. 2000;61(8):575–8.

    Article  CAS  PubMed  Google Scholar 

  22. Kobak KA et al. St John’s wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol. 2005;20(6):299–304.

    Article  PubMed  Google Scholar 

  23. Kobak KA et al. St. John’s wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol. 2005;25(1):51–8.

    Article  PubMed  Google Scholar 

  24. Volz HP et al. St John’s wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl). 2002;164(3):294–300.

    Article  CAS  Google Scholar 

  25. Muller T et al. Treatment of somatoform disorders with St. John’s wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med. 2004;66(4):538–47.

    Article  PubMed  Google Scholar 

  26. Kessler RC et al. Epidemiology of anxiety disorders. Curr Top Behav Neurosci. 2010;2:21–35.

    Article  PubMed  Google Scholar 

  27. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet. 2006;368(9553):2156–66.

    Article  PubMed  Google Scholar 

  28. Newcorn JH, Weiss M, Stein MA. The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. CNS spectr. 2007;12(8 Suppl 12):1–14.

    Article  Google Scholar 

  29. Weber W et al. Hypericum perforatum (St John’s wort) for attention-deficit/hyperactivity disorder in children and adolescents: A randomized controlled trial. JAMA. 2008;299(22):2633–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Schmidt M, Betti G, Hensel A. Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr. 2007;157(13–14):315–9.

    Article  PubMed  Google Scholar 

  31. Hosseinzadeh H, Noraei NB. Anxiolytic and hypnotic effect of Crocus sativus aqueous extract and its constituents, crocin and safranal, in mice. Phytother Res. 2009;23(6):768–74.

    Article  CAS  PubMed  Google Scholar 

  32. Lechtenberg M et al. Quality and functionality of saffron: quality control, species assortment and affinity of extract and isolated saffron compounds to NMDA and sigma1 (sigma-1) receptors. Planta Med. 2008;74(7):764–72.

    Article  CAS  PubMed  Google Scholar 

  33. Hosseinzadeh H, Sadeghnia H. Protective effect of safranal on pentylenetetrazol-induced seizures in the rat: involvement of GABAergic and opioids systems. Phytomedicine. 2007;14(4):256–62.

    Article  CAS  PubMed  Google Scholar 

  34. Pathan SA et al. Quantitative analysis of safranal in saffron extract and nanoparticle formulation by a validated high-performance thin-layer chromatographic method. Phytochem Anal. 2010;21(3):219–23.

    Article  CAS  PubMed  Google Scholar 

  35. Ghadrdoost B et al. Protective effects of saffron extract and its active constituent crocin against oxidative stress and spatial learning and memory deficits induced by chronic stress in rats. Eur J Pharmacol. 2011;667(1–3):222–9.

    Article  CAS  PubMed  Google Scholar 

  36. Nam KN et al. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol. 2010;648(1–3):110–6.

    Article  CAS  PubMed  Google Scholar 

  37. Mehri S et al. Neuroprotectiveeffect of crocin on acrylamide-induced cytotoxicity in PC12 cells.Cell MolNeurobiol. 2011;32(2):227–35.

    Google Scholar 

  38. Akhondzadeh S et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res. 2005;19(2):148–51.

    Article  PubMed  Google Scholar 

  39. Moshiri E et al. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine. 2006;13(9–10):607–11.

    Article  PubMed  Google Scholar 

  40. Akhondzadeh S et al. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med. 2004;4:12.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Noorbala AA et al. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol. 2005;97(2):281–4.

    Article  CAS  PubMed  Google Scholar 

  42. Akhondzadeh B et al. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007;30(2):439–42.

    Article  Google Scholar 

  43. Mischoulon D, Freeman MP. Omega-3 fatty acids in psychiatry. Psychiatr Clin North Am. 2013;36(1):15–23.

    Article  PubMed  Google Scholar 

  44. Rapaport MH et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry. 2015;21(1):71–9.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27(1):24–31.

    Article  CAS  PubMed  Google Scholar 

  46. Tassoni D et al. The role of eicosanoids in the brain. Asia Pac J Clin Nutr. 2008;17(Suppl 1):220–8.

    CAS  PubMed  Google Scholar 

  47. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73(1):81–6.

    Article  CAS  PubMed  Google Scholar 

  48. Stoll A. Omega-3 fatty acids in mood disorders: a review of neurobiological and clinical actions.In: Rosenbaum J,Mischoulon D, editors.Natural medications for psychiatric disorders: considering the alternatives. Philadelphia: Lippincott Williams & Wilkins;2008.p. 39–67.

    Google Scholar 

  49. Hamazaki K et al. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial. Nutrition. 2005;21(6):705–10.

    Article  CAS  PubMed  Google Scholar 

  50. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91(3):757–70.

    Article  CAS  PubMed  Google Scholar 

  51. Lin PY et al. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol Psychiatry. 2012;17(12):1161–3 ; author reply 1163–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Sarris, J., J. Murphy, D. Mischoulon, M. Fava, M. Berk and C. Ng (2016). “Adjunctive Nutrient Nutraceuticals for Depression: A Systematic Review and Meta-analyses.” The American Journal Of Psychiatry; 1;173(6):575-87.

    Google Scholar 

  53. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2009;28(5):525–42.

    Article  CAS  PubMed  Google Scholar 

  54. Mischoulon D et al. A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression. J Clin Psychiatry. 2015;76(1):54–61.

    Article  PubMed  Google Scholar 

  55. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 5):18–22.

    Article  CAS  PubMed  Google Scholar 

  56. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009;70(Suppl 5):12–7.

    Article  CAS  PubMed  Google Scholar 

  57. Alpert JE et al. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002;14(1):33–8.

    Article  PubMed  Google Scholar 

  58. Papakostas GI et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267–74.

    Article  PubMed  Google Scholar 

  59. Williams AL et al. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med. 2005;28(3):132–9.

    CAS  PubMed  Google Scholar 

  60. Baek J, Bernstein E, Nierenberg A. One-carbon metabolism and bipolar disorder. Aust N Z J Psychiatry. 2013;47(11):1013–8.

    Article  PubMed  Google Scholar 

  61. Genedani S et al. Influence of SAMe on the modifications of brain polyamine levels in an animal model of depression. Neuroreport. 2001;12(18):3939–42.

    Article  CAS  PubMed  Google Scholar 

  62. Zomkowski AD, Santos AR, Rodrigues AL. Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(8):1419–25.

    Article  CAS  PubMed  Google Scholar 

  63. Berlanga C et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res. 1992;44(3):257–62.

    Article  CAS  PubMed  Google Scholar 

  64. Papakostas GI et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942–8.

    Article  PubMed  Google Scholar 

  65. Mischoulon D et al. A Double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry2014;75(4):370–6.

    Google Scholar 

  66. Sarris J et al. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord. 2014;164:76–81.

    Article  CAS  PubMed  Google Scholar 

  67. Sarris J, Price LH, Carpenter L, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mischoulon D. Is S-adenosyl methionine (SAMe) for depression only effective in males? A re-analysis of data from a randomized clinical trial. Pharmacopsychiatry. 2015;48(4–5):141–4.

    CAS  PubMed  Google Scholar 

  68. Mischoulon D, Raab MF. The role of folate in depression and dementia. J Clin Psychiatry. 2007;68(Suppl 10):28–33.

    CAS  PubMed  Google Scholar 

  69. Deligiannidis KM, Freeman MP. Complementary and alternative medicine for the treatment of depressive disorders in women. Psychiatr Clin North Am. 33(2):441–63.

    Google Scholar 

  70. Spillmann M, Fava M. S-adenosyl-methionine (ademethionine) in psychiatric disorders. CNS Drugs. 1996;6:416–25.

    Article  CAS  Google Scholar 

  71. Carrieri P et al. S-adenosylmethionine treatment of depressioin in patients with Parkinson’s disease: a double-blind, crossover study versus placebo. Curr Ther Res. 1990;48(1):154–60.

    Google Scholar 

  72. Di Rocco A et al. Adenosyl-Methionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord. 2000;15(6):1225–9.

    Article  CAS  PubMed  Google Scholar 

  73. Szewczyk B, Kubera M, Nowak G. The role of zinc in neurodegenerative inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):693–701.

    Article  CAS  PubMed  Google Scholar 

  74. Swardfager W et al. Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neurosci Biobehav Rev. 2013;37(5):911–29.

    Article  CAS  PubMed  Google Scholar 

  75. Prasad AS. Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009;12(6):646–52.

    Article  CAS  PubMed  Google Scholar 

  76. Yary T, Aazami S. Dietary intake of zinc was inversely associated with depression. Biol Trace Elem Res. 2011;145(3):286–90.

    Article  PubMed  Google Scholar 

  77. Swardfager W et al. Zinc in depression: a meta-analysis. Biol Psychiatry. 2013;74(12):872–8.

    Article  CAS  PubMed  Google Scholar 

  78. Lai J et al. The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord. 2012;136(1–2):e31–9.

    Article  CAS  PubMed  Google Scholar 

  79. Cunha MP et al. Interaction of zinc with antidepressants in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1913–20.

    Article  CAS  PubMed  Google Scholar 

  80. Barrie SA et al. Comparative absorption of zinc picolinate, zinc citrate and zinc gluconate in humans. Agents Actions. 1987;21(1–2):223–8.

    Article  CAS  PubMed  Google Scholar 

  81. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76(5):1158S–61S.

    CAS  PubMed  Google Scholar 

  82. Sarris J. Current challenges in appraising complementary medicine evidence. MJA. 2012;196(5):310–1.

    PubMed  Google Scholar 

  83. Izzo AA. Drug interactions with St. John’s Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther. 2004;42(3):139–48.

    Article  CAS  PubMed  Google Scholar 

  84. Whitten D et al. The effect of St John’s wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol. 2006;62(5):512–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. FDA. http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasSafeGRAS/default.htm. 2012.

  86. Modaghegh MH et al. Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers. Phytomedicine. 2008;15(12):1032–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Melbourne, Department of Psychiatry, The Melbourne Clinic, The Professorial Unit, ARCADIA Mental Health Research Group, 2 Salisbury St, Richmond, Melbourne, VIC, 3121, Australia

    Jerome Sarris

  2. Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, VIC, Australia

    Jerome Sarris

  3. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    David Mischoulon

Authors
  1. Jerome Sarris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Mischoulon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jerome Sarris .

Editor information

Editors and Affiliations

  1. School of Psychology, University of Wollongong, Wollongong, New South Wales, Australia

    David Camfield

  2. School of Psychology, Charles Sturt University, Bathurst, New South Wales, Australia

    Erica McIntyre

  3. Department of Psychiatry Faculty of Medicine, The University of Melbourne, Melbourne, Australia

    Jerome Sarris

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sarris, J., Mischoulon, D. (2017). Treatments for Comorbid Anxiety and Mood Disorders. In: Camfield, D., McIntyre, E., Sarris, J. (eds) Evidence-Based Herbal and Nutritional Treatments for Anxiety in Psychiatric Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-42307-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42307-4_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42305-0

  • Online ISBN: 978-3-319-42307-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation